Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Mutual Funds
Invest in Mutual Funds
Invest in direct mutual funds at zero charges via lump sump investments or SIPs
ITI Pharma and Healthcare Fund Direct Growth
+20.84%
3Y annualised
+1.28% 1D
NAV: 20 Jul '26
₹19.41
Min. for SIP
₹500
Fund size (AUM)
₹251.87 Cr
Expense ratio
0.98%
Rating
2
Return calculator
Monthly investment
₹5,000
| Over the past | Total investment | Would've become | Historic returns | Returns |
|---|---|---|---|---|
| 3 months | ₹15,000 | ₹15,835 | +5.57% | |
| 6 months | ₹30,000 | ₹32,208 | +7.36% | |
| 1 year | ₹60,000 | ₹63,713 | +6.19% | |
| 3 years | ₹1,80,000 | ₹2,19,201 | +21.78% |
Holdings (38)
| Name | Sector | Instruments | Assets |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | Equity | 13.34% |
| Divi's Laboratories Ltd | Healthcare | Equity | 6.79% |
| Apollo Hospitals Enterprise Ltd | Healthcare | Equity | 6.22% |
| Dr. Reddy's Laboratories Ltd | Healthcare | Equity | 5.44% |
| Max Healthcare Institute Ltd | Healthcare | Equity | 5.41% |
| Cipla Ltd | Healthcare | Equity | 4.60% |
| Torrent Pharmaceuticals Ltd | Healthcare | Equity | 4.56% |
| Laurus Labs Ltd | Healthcare | Equity | 4.40% |
| Aurobindo Pharma Ltd | Healthcare | Equity | 4.10% |
| Lupin Ltd | Healthcare | Equity | 3.30% |
| Net Receivables | Unspecified | Net Receivables | 3.22% |
| Neuland Laboratories Ltd | Healthcare | Equity | 3.09% |
| Fortis Healthcare Ltd | Healthcare | Equity | 2.94% |
| Suven Pharmaceuticals Ltd | Healthcare | Equity | 2.89% |
| Mankind Pharma Ltd. | Healthcare | Equity | 2.84% |
| Alkem Laboratories Ltd | Healthcare | Equity | 2.75% |
| Global Health Ltd | Healthcare | Equity | 2.01% |
| Abbott India Ltd | Healthcare | Equity | 1.82% |
| Aster DM Healthcare Ltd | Healthcare | Equity | 1.54% |
| Ipca Laboratories Ltd | Healthcare | Equity | 1.52% |
| Sai Life Sciences Ltd. | Healthcare | Equity | 1.30% |
| Poly Medicure Ltd | Healthcare | Equity | 1.28% |
| Linde India Ltd | Materials | Equity | 1.25% |
| Shaily Engineering Plastics Ltd | Materials | Equity | 1.22% |
| Shilpa Medicare Ltd | Healthcare | Equity | 1.18% |
| Piramal Pharma Ltd | Healthcare | Equity | 1.14% |
| Glenmark Pharmaceuticals Ltd | Healthcare | Equity | 1.12% |
| Healthcare Global Enterprises Ltd | Healthcare | Equity | 1.09% |
| Supriya Lifescience Ltd | Healthcare | Equity | 1.03% |
| Rainbow Childrens Medicare Ltd | Healthcare | Equity | 1.02% |
| Biocon Ltd | Healthcare | Equity | 0.97% |
| Venus Pipes & Tubes Ltd | Industrials | Equity | 0.95% |
| Glaxosmithkline Pharmaceuticals Ltd | Healthcare | Equity | 0.90% |
| Zydus Lifesciences Ltd | Healthcare | Equity | 0.74% |
| Caplin Point Laboratories Ltd | Healthcare | Equity | 0.59% |
| Bharat Dynamics Ltd | Industrials | Equity | 0.54% |
| Yes Bank Ltd | Financial | Equity | 0.51% |
| Syngene International Ltd | Healthcare | Equity | 0.39% |
See All
Minimum investments
Min. for 1st investment
₹5,000
Min. for 2nd investment
₹1,000
Min. for SIP
₹500
Returns and rankings
Annualised returns
Absolute returns
| Name | 6M | 1Y | 3Y | All |
|---|---|---|---|---|
| Fund returns | +20.1% | +7.8% | +20.8% | +15.2% |
| Category average (Equity Sectoral) | +0.2% | -2.1% | +22.1% | -- |
| Rank (Equity Sectoral) | -- | 23 | 12 | -- |
Exit load, stamp duty and tax
Exit load
Exit load of 0.50%, if redeemed within 3 months.
Stamp duty on investment: 0.005% (from July 1st, 2020)
from July 1st 2020
Tax implication
If you redeem within one year, returns are taxed at 20%. If you redeem after one year, returns exceeding Rs 1.25 lakh in a financial year are taxed at 12.5%.
Check past data
Fund management
RBRajesh BhatiaJun 2024 - PresentView details
RB
Rajesh Bhatia
Jun 2024 - Present
View details
ASAnimesh SinghMay 2026 - PresentView details
AS
Animesh Singh
May 2026 - Present
View details
NDNilay DalalMay 2026 - PresentView details
ND
Nilay Dalal
May 2026 - Present
View details
About ITI Pharma and Healthcare Fund Direct Growth
ITI Pharma and Healthcare Fund Direct Growth is a Equity Mutual Fund Scheme launched by ITI Mutual Fund. This scheme was made available to investors on 14 May 2018. Rajesh Bhatia is the Current Fund Manager of ITI Pharma and Healthcare Fund Direct Growth fund. The fund currently has an Asset Under Management(AUM) of ₹11,989 Cr and the Latest NAV as of 20 Jul 2026 is ₹19.41.
The ITI Pharma and Healthcare Fund Direct Growth is rated Very High risk. Minimum SIP Investment is set to ₹500. Minimum Lumpsum Investment is ₹5,000. Exit load of 0.50%, if redeemed within 3 months.
;
Investment Objective
The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare.
Fund benchmarkNIFTY Healthcare Total Return Index.
Fund house
Rank (total assets)--
Total AUM₹11,988.92 Cr
Date of Incorporation14 May 2018
Launch Date14 May 2018
AddressITI Asset Mangement Limited,ITI House, Building no. 36,Dr. R. K. Shirodkar Marg, Parel, Mumbai 400012
Websitewww.karvymfs.com
AddressKarvy House, No. 46, 8-2-609/K, Avenue 4, Street No.1 Banjara Hills,